Sorafenib

製品コードS7397 別名:BAY 43-9006

Sorafenib化学構造

分子量(MW):464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 24402.00
JPY 44820.00
JPY 111220.00

文献中の使用例(62)

カスタマーフィードバック(9)

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
ターゲット
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NXnmbW5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMECwNFA{ODNizszN M1rUe3NCVkeHUh?=
MONO-MAC-6 NXfXfVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrwTWM2OD1yLkCwOFE5KM7:TR?= NUXhb5lIW0GQR1XS
ALL-PO NUOxPJRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEOxPFQh|ryP M4TH[XNCVkeHUh?=
NKM-1 NWPKWoVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KxNmlEPTB;MD6wO|QyPiEQvF2= MVXTRW5ITVJ?
CGTH-W-1 MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTJUHQ1UUN3ME2wMlI2ODJ{IN88US=> NEjTeHlUSU6JRWK=
BB65-RCC M3Lnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtUGlKSzVyPUCuOFcxPzNizszN NWrEVY1rW0GQR1XS
NOS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjzRnBKSzVyPUCuOVY{PiEQvF2= NGjVeZdUSU6JRWK=
SH-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;qTWM2OD1yLk[1OlE{KM7:TR?= NYrJepd[W0GQR1XS
HOP-62 NHnqR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLFSZZKSzVyPUCuPFUxQDhizszN M1THV3NCVkeHUh?=
HCC2998 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3yyOmlEPTB;MD64PFgyQCEQvF2= MYrTRW5ITVJ?
GDM-1 NVT0SmFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO0TWM2OD1yLkmwOlk5KM7:TR?= NF;leo1USU6JRWK=
KM12 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfabY1KSzVyPUGuNFIxQThizszN NIPqWGVUSU6JRWK=
LB2518-MEL MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfye4c2UUN3ME2xMlIxQDB7IN88US=> M3\5[HNCVkeHUh?=
NCI-H1436 NE\EdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnvTXNNUUN3ME2xMlIyPjd6IN88US=> MX;TRW5ITVJ?
EM-2 NVvHfVNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwM{W1O|gh|ryP NXLSd4tsW0GQR1XS
LAMA-84 NEXrZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHDTWM2OD1zLkO3OlQ5KM7:TR?= M{nBTnNCVkeHUh?=
KG-1 NFq2U3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;YXmVnUUN3ME2xMlQ4QTN3IN88US=> MYrTRW5ITVJ?
A388 NGXINHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX4VINKSzVyPUGuOVkyPjVizszN M4\KfnNCVkeHUh?=
no-10 NGrUOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPDOFJKSzVyPUGuOlE4OjZizszN NYq1bYlPW0GQR1XS
SF126 NHTjSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:4TWM2OD1zLk[zPFEzKM7:TR?= NEn4RpVUSU6JRWK=
MEG-01 NVKycG17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrDTItRUUN3ME2xMlgxQThizszN MXfTRW5ITVJ?
A3-KAW MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfYUGxOUUN3ME2xMlg5PDJizszN NInKWZlUSU6JRWK=
D-247MG NVyxbJk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwMUS0PEDPxE1? MWDTRW5ITVJ?
OVCAR-4 NEWwUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnVOXAyUUN3ME2yMlIyOzl|IN88US=> M4rVSHNCVkeHUh?=
NCI-SNU-1 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXJUHA3UUN3ME2yMlMyPjJizszN MlfJV2FPT0WU
NCI-H2171 M2Tuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuwR3lKSzVyPUKuN|k4PjRizszN NXX1N4VjW0GQR1XS
SIG-M5 M1[yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi4NohKSzVyPUKuOFIzPDJizszN MnfqV2FPT0WU
BE-13 NHrINVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrDWmJKSzVyPUKuOlk3ODlizszN NFPaTJpUSU6JRWK=
K052 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqT2lEPTB;Mj63OFYyPiEQvF2= NH;LdXJUSU6JRWK=
L-540 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SzO2lEPTB;Mj63OVc5QSEQvF2= MXfTRW5ITVJ?
KMOE-2 M1rUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\GcGlEPTB;Mj64NVM2KM7:TR?= M3XRRnNCVkeHUh?=
MFH-ino M2HwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwOUKxPFUh|ryP M3e3dHNCVkeHUh?=
HL-60 NUjrW3F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle0TWM2OD1|LkC2Nlk6KM7:TR?= NFnsOGdUSU6JRWK=
HCC2218 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjRTYZoUUN3ME2zMlEzODB|IN88US=> Mn[1V2FPT0WU
TE-5 NFfsNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrwV4hKSzVyPUOuNVMyPjJizszN NYrNZ3hPW0GQR1XS
MZ1-PC NWXKb2dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfhTWM2OD1|LkS3OVA6KM7:TR?= NGfsRVhUSU6JRWK=
MRK-nu-1 M1;teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTNwNkG0Olgh|ryP NXjSUpE6W0GQR1XS
MZ7-mel NYWxVplUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPiRWRkUUN3ME2zMlY3ODl7IN88US=> NH;VPYZUSU6JRWK=
BC-1 NIi1PWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjpRZhGUUN3ME2zMlc1ODJizszN Ml\RV2FPT0WU
ST486 M3XTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Syd2lEPTB;Mz64N|Y4OyEQvF2= MWnTRW5ITVJ?
KS-1 NVzKfGN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwOEixPVgh|ryP NIXlb3hUSU6JRWK=
SK-NEP-1 NVfrW4VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwMU[4NVUh|ryP M2\wfHNCVkeHUh?=
BC-3 NFy0XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXZ[YhKSzVyPUSuNlM{QTFizszN MXjTRW5ITVJ?
NCI-H1581 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fDRmlEPTB;ND6yPFc6QCEQvF2= M1i5dHNCVkeHUh?=
MHH-PREB-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRwNEC0PFQh|ryP NUHPbFFZW0GQR1XS
NOMO-1 NHTHZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv5R2tDUUN3ME20MlQ5QTB3IN88US=> NGrPTHpUSU6JRWK=
QIMR-WIL M33uNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XzeGlEPTB;NT6wO|I6PCEQvF2= M3u5RnNCVkeHUh?=
SF539 NYXuUlU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6dY1wUUN3ME21MlE{OjJ5IN88US=> M3\PcXNCVkeHUh?=
TE-12 M{jsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT4TWM2OD13LkK0PVI6KM7:TR?= MYXTRW5ITVJ?
NCI-H510A M{fJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfkdJZJUUN3ME21MlQyPjh3IN88US=> NHWzWphUSU6JRWK=
JAR NInyRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3CTWM2OD13LkWwPFI1KM7:TR?= NYe5XWd3W0GQR1XS
no-11 NY[xXo94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrPVlhKSzVyPUWuO|M2PjhizszN NGfTSXFUSU6JRWK=
BV-173 M4Th[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[zTWM2OD13Lkm1OlgzKM7:TR?= NIPCe5FUSU6JRWK=
SR NGGwTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXniXlNoUUN3ME22MlAxPjd6IN88US=> M4TRc3NCVkeHUh?=
MOLT-16 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH3TWM2OD14LkK1NlY3KM7:TR?= MWjTRW5ITVJ?
MZ2-MEL M{DGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n0TWlEPTB;Nj6zNVg{QSEQvF2= NIj2PIZUSU6JRWK=
SW954 M2\5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZwNEW4OlYh|ryP MVHTRW5ITVJ?
ML-2 NILtcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{juUWlEPTB;Nj61Nlg1QSEQvF2= M2XifXNCVkeHUh?=
OCI-AML2 NIHyfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHHNlBUUUN3ME22MlYyODZ{IN88US=> NHLhXFdUSU6JRWK=
SIMA NW\yOZZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\tfVF1UUN3ME23MlAxOTBzIN88US=> NHPJfmRUSU6JRWK=
DOHH-2 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KwbmlEPTB;Nz6wOVY4PiEQvF2= NILaRoZUSU6JRWK=
697 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\zNlVqUUN3ME23MlA2QTh7IN88US=> NWW0WHN[W0GQR1XS
NB1 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTdwNEC0NFch|ryP M3jNOHNCVkeHUh?=
D-392MG NX\F[Xh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\meHBKSzVyPUeuOlI3PjNizszN MnTPV2FPT0WU
ES8 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOzTIxKSzVyPUeuO|Y2ODNizszN MX\TRW5ITVJ?
RPMI-8226 MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV25eJZkUUN3ME23Mlg1PTFzIN88US=> M4HmOnNCVkeHUh?=
IST-MEL1 NV7O[5RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjOTWM2OD16LkSwNFAzKM7:TR?= MUDTRW5ITVJ?
NB14 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED5NGhKSzVyPUiuOlMyOzNizszN NU\JfodrW0GQR1XS
HD-MY-Z MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rwU2lEPTB;OD62N|c1PiEQvF2= NYPEepcyW0GQR1XS
TE-10 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRThwN{[zOVMh|ryP NVf2N4xbW0GQR1XS
LC-1F NYH0UZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLyTWM2OD17LkGwPFM1KM7:TR?= MYnTRW5ITVJ?
OS-RC-2 NWTiR5pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwMUGyOFMh|ryP NUXTZ5Z2W0GQR1XS
NCI-SNU-16 M33BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKzTWM2OD17LkKxNFI3KM7:TR?= MXzTRW5ITVJ?
SHP-77 NHjPdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LZdWlEPTB;OT63NVY3OiEQvF2= M1K5NHNCVkeHUh?=
A4-Fuk NVLVVphKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3WZYxiUUN3ME25Mlc2PjFizszN MYnTRW5ITVJ?
NB6 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuy[5RKSzVyPUmuO|YxOjlizszN NX;YbXJ1W0GQR1XS
JiyoyeP-2003 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrJVmtKSzVyPUGwMlQ4PDVizszN MoLXV2FPT0WU
DMS-114 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInBW2VKSzVyPUGwMlU1PDFizszN NYS1NnZ3W0GQR1XS
NB7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjPTWM2OD1zMD63OVI3KM7:TR?= MU\TRW5ITVJ?
NCI-H747 NEW0XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ob2lEPTB;MUGuNVIyPiEQvF2= NHPvXopUSU6JRWK=
HH M4HwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX1TWM2OD1zMT6zPFc3KM7:TR?= NHPOb|BUSU6JRWK=
EW-18 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHQTWM2OD1zMT65NFQ1KM7:TR?= NYDkTlU6W0GQR1XS
CHP-126 NILkc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXaU455UUN3ME2xNU46PzN6IN88US=> NW\oXG81W0GQR1XS
NTERA-S-cl-D1 M1T6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn4TWM2OD1zMj6wNlc5KM7:TR?= NVnFZnBoW0GQR1XS
DEL MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm2doJGUUN3ME2xNk4xQTh3IN88US=> M{fHVXNCVkeHUh?=
LU-139 NFrLVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD1zMj61OFE{KM7:TR?= NHzSfnVUSU6JRWK=
P30-OHK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGra[nZKSzVyPUGyMlU1PzlizszN NFL1XmFUSU6JRWK=
NCI-H1522 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rlSmlEPTB;MUKuO|Q3KM7:TR?= NXPSfohjW0GQR1XS
NCI-H1299 NYj1e3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKwNoJHUUN3ME2xN{4zQTFzIN88US=> MVPTRW5ITVJ?
UACC-257 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHRPVF4UUN3ME2xN{42OTJ4IN88US=> NHTJSJJUSU6JRWK=
Calu-6 NH;WNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\6e4VKSzVyPUGzMlYxPDZizszN NXfjcIFvW0GQR1XS
NCI-H1882 NWjrUZlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILBb2RKSzVyPUGzMlg2PTVizszN NF[wZY9USU6JRWK=
BB30-HNC NYLnfYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF2LkC2NFkh|ryP M2rxXnNCVkeHUh?=
ES1 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF2LkG1OVEh|ryP M4rubHNCVkeHUh?=
NCI-H1694 NIO5V|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF2LkS4NVEh|ryP MkfMV2FPT0WU
IST-SL1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS4TWM2OD1zND65OlE3KM7:TR?= Mn\QV2FPT0WU
ECC4 M{D3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jIZWlEPTB;MUWuNFU2QCEQvF2= NHfK[nhUSU6JRWK=
MDA-MB-134-VI NXPNbmZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzMfFBKSzVyPUG1MlQyOzFizszN M3;W[HNCVkeHUh?=
SCH Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLZTWM2OD1zNT60O|I5KM7:TR?= MVnTRW5ITVJ?
SK-N-FI NXjoepdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPOcmtKSzVyPUG1MlY2OzRizszN NGHO[4ZUSU6JRWK=
HDLM-2 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfIe|ROUUN3ME2xOk4xPzF2IN88US=> NHu1NVNUSU6JRWK=
Ramos-2G6-4C10 NX\rV3BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF4LkGyPVch|ryP MlO1V2FPT0WU
EW-24 Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF4LkG2OlEh|ryP MmX5V2FPT0WU
NCI-H2141 NWS3UYtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\kTWlEPTB;MU[uNVg6KM7:TR?= NFKxVJZUSU6JRWK=
LC4-1 NX3nWohvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni3TWM2OD1zNj62NVE6KM7:TR?= NYrNSY0zW0GQR1XS
HT-144 NWfGW5o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2ZYxlUUN3ME2xO{4xODZizszN MYfTRW5ITVJ?
SK-MEL-1 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LQNWlEPTB;MUeuNFA4OiEQvF2= M4XPR3NCVkeHUh?=
SCC-15 M4fXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHaUZpKSzVyPUG3MlE3OzhizszN NFf3b4lUSU6JRWK=
C8166 NFnGfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPsSpNEUUN3ME2xO{43QDN|IN88US=> NV;le41kW0GQR1XS
GOTO M2\MbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\BbXI2UUN3ME2xO{45OzR2IN88US=> MkL1V2FPT0WU
COR-L279 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLydmQ{UUN3ME2xPE4yOzZ{IN88US=> NXjGT5VQW0GQR1XS
K-562 NUT0fYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfFRYpKSzVyPUG4MlcyPDNizszN MnvuV2FPT0WU
ES3 M4nFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r5UGlEPTB;MUiuPFA1OSEQvF2= NFzn[ZlUSU6JRWK=
LU-165 NF;RXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fNPWlEPTB;MUmuO|AxQCEQvF2= NXOyXFloW0GQR1XS
KM-H2 NIfsXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJyLkOxPFQh|ryP MoDkV2FPT0WU
RL NF33THdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nFbWlEPTB;MkCuPVY6OiEQvF2= NFLaNmRUSU6JRWK=
EW-3 M{TCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJzLkG4PFkh|ryP MX3TRW5ITVJ?
A101D Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zNdWlEPTB;MkGuN|c2OiEQvF2= MlSxV2FPT0WU
HUTU-80 M1zuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3wTWM2OD1{MT6zPVQ3KM7:TR?= MkfJV2FPT0WU
NCI-H23 NF3VNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHrcIwzUUN3ME2yNU4{QTl{IN88US=> Mn\ZV2FPT0WU
PF-382 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\M[2lEPTB;MkGuOFQxOyEQvF2= M3vUXnNCVkeHUh?=
LB373-MEL-D MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWyTWM2OD1{MT61OlE2KM7:TR?= M2GwUHNCVkeHUh?=
TE-8 NFK3XWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH6V3hKSzVyPUKxMlY{QTRizszN NF\qVlJUSU6JRWK=
TE-9 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ZTWM2OD1{MT64OVE{KM7:TR?= MVnTRW5ITVJ?
Daudi NGDa[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\ZTWM2OD1{MT65N|A1KM7:TR?= NVnZR4UyW0GQR1XS
D-542MG NGDiTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0ZVZPUUN3ME2yNk4xOjV4IN88US=> NXjYPIw1W0GQR1XS
U-698-M M4noRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ{LkS2NFMh|ryP MoTIV2FPT0WU
ES6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf0WnNKSzVyPUKyMlc{PjZizszN M{fI[HNCVkeHUh?=
DU-4475 NVi3b45xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3SdldKSzVyPUKzMlg5QTdizszN M3;LTXNCVkeHUh?=
ECC12 NV[y[Xh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmwTWM2OD1{ND6yPFA{KM7:TR?= MYTTRW5ITVJ?
C2BBe1 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXuTWM2OD1{ND6zNlM6KM7:TR?= MXzTRW5ITVJ?
IST-SL2 M{D0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj5TFlKSzVyPUK0MlQ{PjJizszN M{PuPXNCVkeHUh?=
DJM-1 NXn6em1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\MZXhKSzVyPUK0MlUzOjFizszN NELISppUSU6JRWK=
DMS-153 M{DiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ2Lki2NVQh|ryP M2TwVHNCVkeHUh?=
NB13 M1:4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu0fIh[UUN3ME2yOU4xOjZ3IN88US=> NETOVHFUSU6JRWK=
SK-N-DZ NYfNRmprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ4LkO0NVQh|ryP MXLTRW5ITVJ?
COR-L88 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP3VpJRUUN3ME2yOk42Pzl4IN88US=> M{TjNnNCVkeHUh?=
LU-65 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfDTWM2OD1{Nj64OVM2KM7:TR?= NHflPFJUSU6JRWK=
TGBC1TKB MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7FeXRMUUN3ME2yOk46QDJ6IN88US=> MoLCV2FPT0WU
THP-1 M1jGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ5LkKxOFEh|ryP NEn2VpBUSU6JRWK=
ONS-76 NYWxSpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ5LkOzNkDPxE1? MlfhV2FPT0WU
LC-2-ad MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ5Lk[yN|Eh|ryP NWrZeJhHW0GQR1XS
EW-13 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG1TWM2OD1{OT6xO|Q3KM7:TR?= M1LVSXNCVkeHUh?=
MS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPJc3k{UUN3ME2zNE44Ojd6IN88US=> NW\Y[FBTW0GQR1XS
NCI-H2227 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnwdYpKSzVyPUOwMlk5ODZizszN NF63coVUSU6JRWK=
LXF-289 M4nR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTiTWM2OD1|MT60OFkzKM7:TR?= Ml;CV2FPT0WU
MC116 NXPMRYdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN{LkC4NlYh|ryP NYe5[YpkW0GQR1XS
EVSA-T M{XrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN{LkK1PFUh|ryP M13mT3NCVkeHUh?=
CTB-1 M2naN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor5TWM2OD1|Mz6xNVAyKM7:TR?= MYjTRW5ITVJ?
COLO-320-HSR M1:0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm0d5FKSzVyPUOzMlE3ODNizszN MkC5V2FPT0WU
NCI-H2196 NGnGT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yweGlEPTB;M{OuNlU2PyEQvF2= NVezZmo5W0GQR1XS
LB2241-RCC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO0dW01UUN3ME2zN{4{OTN3IN88US=> M2DGV3NCVkeHUh?=
LS-513 NUHGeIZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv3TWM2OD1|Mz64OlM5KM7:TR?= MkfIV2FPT0WU
LP-1 NHnLUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[ze5dFUUN3ME2zN{46QTV4IN88US=> MYfTRW5ITVJ?
A253 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknZTWM2OD1|ND6yNlk3KM7:TR?= MVTTRW5ITVJ?
SK-MM-2 NYjjUml3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TsO2lEPTB;M{SuPVQ2OSEQvF2= MlfVV2FPT0WU
NCI-H1963 M1XXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnueHBPUUN3ME2zOU4{ODd{IN88US=> NF\SR3ZUSU6JRWK=
MMAC-SF MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfiTWM2OD1|NT64O|g2KM7:TR?= NGn2RWJUSU6JRWK=
LB831-BLC NFXWO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu4TWM2OD1|Nj6wOlU1KM7:TR?= Mm\OV2FPT0WU
WSU-NHL MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjJXWFHUUN3ME2zOk4yPjRizszN NVTnUotnW0GQR1XS
CESS NF\iR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GyS2lEPTB;M{[uNlg1QCEQvF2= Mn7lV2FPT0WU
NEC8 NInWW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHyb2R5UUN3ME2zOk42QDN3IN88US=> MUPTRW5ITVJ?
KNS-42 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO3V4NKSzVyPUO3MlEzOzdizszN NF3mVXlUSU6JRWK=
MHH-CALL-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPTZXNKSzVyPUO3MlE5OjFizszN NIKwOoVUSU6JRWK=
K5 NXjLe2dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;jZmlEPTB;M{iuOFMh|ryP MUHTRW5ITVJ?
CP66-MEL NVf1XVRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP0Z3dTUUN3ME2zPU4xPzN|IN88US=> NVLFO2FCW0GQR1XS
OPM-2 M4n5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PBeWlEPTB;M{muPFQ{OiEQvF2= MUfTRW5ITVJ?
IST-MES1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\Ld3BKSzVyPUSwMlMxQTZizszN NYr3XHh5W0GQR1XS
EC-GI-10 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPt[HBKSzVyPUSxMlU5ODVizszN NHvSe4ZUSU6JRWK=
CTV-1 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T6PGlEPTB;NEKuPFQxPiEQvF2= M2XKfXNCVkeHUh?=
DG-75 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\OTWM2OD12Mz63OVk2KM7:TR?= NFr6SXBUSU6JRWK=
KNS-81-FD NYHXTZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkixTWM2OD12NT60NFU5KM7:TR?= NEC0VZRUSU6JRWK=
NCI-H82 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPVTWM2OD12NT61O|U5KM7:TR?= Mn7BV2FPT0WU
RPMI-8866 NWLnfnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETPVGFKSzVyPUS2MlE5PzNizszN MW\TRW5ITVJ?
ACN M2nadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR4LkSzOEDPxE1? NHfx[WtUSU6JRWK=
NCI-H1395 NFzWPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHuTWM2OD12Nj60O|U3KM7:TR?= NX[1UG5wW0GQR1XS
NCI-H209 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2SzRWlEPTB;NEeuNVQxPSEQvF2= MUHTRW5ITVJ?
TGW NXztNIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DobWlEPTB;NEmuNFc6OSEQvF2= M4XXRnNCVkeHUh?=
NCI-H748 NXXNUWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfHV|BKSzVyPUS5MlQ4PTNizszN M1;RR3NCVkeHUh?=
EKVX M2HwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zjW2lEPTB;NEmuOlYzQCEQvF2= MVfTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験:

[1]

+ 展開
  • 細胞株: MDA-MB-231, and HAoSMC
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • 製剤: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • 投薬量: ~60 mg/kg
  • 投与方法: Orally once daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 63 mg/mL (135.53 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 400+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 464.82
化学式

C21H16ClF3N4O3

CAS No. 284461-73-0
保管
in solvent
別名 BAY 43-9006

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Rafシグナル伝達経路

相関Raf製品

Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID